Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 53

Sort by

Sort Order Select

Journal Articles

Safety, tolerability, and activity of the active C1s antibody riliprubart in cold agglutinin disease: a phase 1b study

Shirley D’Sa, Josephine M. I. Vos, Wilma Barcellini, Marek Wardęcki, Laurent Perrin, Graham Barker, Moshe Zilberstein, Michael Storek, Timothy Chow, Alexander Röth

Blood (2024) 143 (8): 713–720.

https://doi.org/10.1182/blood.2023022153

Published: 2024

Includes: Supplemental data

Journal Articles

Using a Quality Improvement Activity to Enhance the Knowledge, Competence and Confidence of Clinicians Managing Patients with Cold Agglutinin Disease

Alison Scott, Bernd Jilma, Morie A Gertz, Shirley D'Sa, Luke Boothman, Alex Noble, Kathy Day, Sadaf Kazi

Blood (2023) 142 (Supplement 1): 5066.

https://doi.org/10.1182/blood-2023-172507

Published: 2023

Journal Articles

Ethnic Diversity in Presentation of Waldenström Macroglobulinaemia and IgM Mgcs in the United Kingdom- a Real-World Data Analysis

Jahanzaib Khwaja, Nicole Japzon, Maria Gabriel, Charles Lilley, Charalampia Kyriakou, Ali Rismani, Shirley D'Sa

Blood (2023) 142 (Supplement 1): 1668.

https://doi.org/10.1182/blood-2023-186561

Published: 2023

Journal Articles

Modified Staging System for Waldenström Macroglobulinemia (MSS-WM): A Multi-Institutional Externally Validated Prognostic Model for Active/Symptomatic Waldenström Macroglobulinemia

Blood (2023) 142 (Supplement 1): 3030.

https://doi.org/10.1182/blood-2023-179940

Published: 2023

Journal Articles

Classical Complement Inhibition By SAR445088 (BIVV020) in Adults with Cold Agglutinin Disease: Safety, Tolerability and Activity Results from the Open-Label, Non-Randomized, Single-Dose Phase 1b Study

Shirley D'Sa, Josephine M.I. Vos, Wilma Barcellini, Marek Wardęcki, Laurent Perrin, Graham Barker, Moshe Zilberstein, Michael Storek, Timothy Chow, Alexander Roeth

Blood (2023) 142 (Supplement 1): 1069.

https://doi.org/10.1182/blood-2023-177886

Published: 2023

Journal Articles

Pembrowm: Results of a Multi-Centre Phase II Trial Investigating the Safety and Efficacy of Rituximab and Pembrolizumab in Relapsed/Refractory Waldenström's Macroglobulinaemia

Jaimal Kothari, Toby A. Eyre, Ali Rismani, Helen McCarthy, Angela Collins, David John Lewis, Suzanne O Arulogun, William Wilson, Laura Clifton-Hadley, Darren Edwards, Kushani Ediriwickrema, Rebecca Auer, Guy Pratt, Ruth M. de Tute, Roger G Owen, Shirley D'Sa

Blood (2022) 140 (Supplement 1): 3624–3626.

https://doi.org/10.1182/blood-2022-167158

Published: 2022

Journal Articles

Type 1 Cryoglobulinaemia Associated with Waldenström Macroglobulinemia, IgM MGUS or Non-Hodgkin Lymphoma

Jahanzaib Khwaja, Simon Salter, Aisha S Patel, Robert Baker, Rajeev Gupta, Ali Rismani, Charalampia Kyriakou, Ashutosh D. Wechalekar, Josephine M.I. Vos, Shirley D'Sa

Blood (2022) 140 (Supplement 1): 3653–3654.

https://doi.org/10.1182/blood-2022-160438

Published: 2022

Journal Articles

Adjuvant Systemic Therapy in High Risk Solitary Bone Plasmacytoma: Results of the UK Randomised Phase III IDRIS Study (CR UK/14/032)

Kushani Ediriwickrema, Neil K Rabin, Shirley D'Sa, Graham Jackson, Peter Hoskin, Eve Gallop-Evans, Patricia Diez, Catherine Parbutt, Andre Lopes, Sevasti Galani, Laura Clifton-Hadley, Darren Edwards, Husne Timur Tezver, Ruth M. de Tute, Andrew Bates, Roger G Owen

Blood (2022) 140 (Supplement 1): 12626–12627.

https://doi.org/10.1182/blood-2022-158528

Published: 2022

Journal Articles

Addressing Clinical Management Challenges in the Treatment of Rare, Non-Malignant Hematologic Disorders through Educational Interventions

Sumera Ackbarali, Tariqa Ackbarali, Katie Kowalski, Hans C. Lee, Vaishali Sanchorawala, Shirley D'Sa, Satheesh Chonat, Carlos M. de Castro

Blood (2022) 140 (Supplement 1): 13057–13058.

https://doi.org/10.1182/blood-2022-157219

Published: 2022

Journal Articles

Sustained Complement C1s Inhibition with Sutimlimab in Patients with Cold Agglutinin Disease Results in Continued Efficacy during Part B of the Randomized Placebo-Controlled Phase 3 Cadenza Study (NCT03347422)

Blood (2022) 140 (Supplement 1): 2825–2827.

https://doi.org/10.1182/blood-2022-159562

Published: 2022

Journal Articles

Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial

Alexander Röth, Sigbjørn Berentsen, Wilma Barcellini, Shirley D’Sa, Bernd Jilma, Marc Michel, Ilene C. Weitz, Masaki Yamaguchi, Jun-ichi Nishimura, Josephine M. I. Vos, Michael Storek, Nancy Wong, Parija Patel, Xiaoyu Jiang, Deepthi S. Vagge, Marek Wardęcki, Frank Shafer, Michelle Lee, Catherine M. Broome

Blood (2022) 140 (9): 980–991.

https://doi.org/10.1182/blood.2021014955

Published: 2022

Includes: Supplemental data

Journal Articles

Effect of ibrutinib treatment on hemolytic anemia and acrocyanosis in cold agglutinin disease/cold agglutinin syndrome

Marit Jalink, Sigbjørn Berentsen, Jorge J. Castillo, Steven P. Treon, Marjan Cruijsen, Bruno Fattizzo, Ramona Cassin, Despina Fotiou, Efstathios Kastritis, Masja De Haas, Liesbeth E. M. Oosten, Henrik Frederiksen, Andrea Patriarca, Shirley D'Sa, Josephine M.I. Vos

Blood (2021) 138 (20): 2002–2005.

https://doi.org/10.1182/blood.2021012039

Published: 2021

Includes: Supplemental data

Journal Articles

High Frequency of CNS Involvement in Transformed Waldenström Macroglobulinemia

Blood (2021) 138 (Supplement 1): 2526.

https://doi.org/10.1182/blood-2021-145440

Published: 2021

Journal Articles

Inhibition of Complement C1s By Sutimlimab in Patients with Cold Agglutinin Disease (CAD): Efficacy and Safety Results from the Randomized, Placebo-Controlled Phase 3 CADENZA Study

Blood (2021) 138 (Supplement 1): 349.

https://doi.org/10.1182/blood-2021-148066

Published: 2021

Journal Articles

Ethnic Disparities in Waldenström's Macroglobulinaemia in the United Kingdom - Analysis from the Wmuk Rory Morrison Registry

Blood (2021) 138 (Supplement 1): 1977.

https://doi.org/10.1182/blood-2021-153590

Published: 2021

Journal Articles

Real World Experience on the Use of Ibrutinib Monotherapy in Waldenström Macroglobulinemia

Olabisi Ogunbiyi, Suzanne O Arulogun, Aisha Patel, Ali Rismani, Charalampia Kyriakou, Shirley D'Sa

Blood (2021) 138 (Supplement 1): 4507.

https://doi.org/10.1182/blood-2021-153714

Published: 2021

Journal Articles

IgM Paraprotein-Associated Type 1 Cryoglobulinaemia: Clinical Characteristics and Outcomes

Jahanzaib Khwaja, Aisha S Patel, Suzanne O Arulogun, Ali Rismani, Simon Salter, Charalampia Kyriakou, Josephine M.I. Vos, Shirley D'Sa

Blood (2021) 138 (Supplement 1): 4503.

https://doi.org/10.1182/blood-2021-151662

Published: 2021

Journal Articles

Autologous Haematopoietic Stem Cell Transplantation in Waldenström Macroglobulinemia: A Single-Centre 18-Year Experience

Suzanne O Arulogun, Charalampia Kyriakou, Jackie Horder, Fiona Newrick, Aisha S Patel, Ali Rismani, Kwee Yong, Ashutosh D. Wechalekar, Shirley D'Sa

Blood (2021) 138 (Supplement 1): 3548.

https://doi.org/10.1182/blood-2021-150637

Published: 2021

Journal Articles

Global Waldenström's Macroglobulinemia Patient-Derived Data Registry, Whimsical, Highlights Real-World Treatment Outcomes and COVID-19 Data

Ibrahim Tohidi-Esfahani, Andrew Warden, Elena Malunis, Peter Liburdi deNardis, Michelle Postek, Shirley D'Sa, Marie José Kersten, Sheeba K Thomas, M. Lia Palomba, Adam J. Olszewski, Newton Guerin, Clare Scott, Judith Trotman

Blood (2021) 138 (Supplement 1): 1343.

https://doi.org/10.1182/blood-2021-147720

Published: 2021

Journal Articles

Whimsical (Waldenstrom's Macroglobulinemia Study Involving CArt-wheeL): A Global Patient-Derived Data Registry Capturing Treatment, Quality of Life and COVID-19 Data

Ibrahim Tohidi-Esfahani, MBBS,FRACP,FRCPA, Andrew Warden, Elena Malunis, Peter Liburdi deNardis, Javier Haurat, Marita Black, Stephen Opat, MBBS (Hons), FRACP, FRCPA, Shirley D'Sa, MD FRCPath, Marie José Kersten, MD PhD, Ruth Spearing, MD, Maria Lia Palomba, Adam J Olszewski, MD, Carl Harrington, Clare Scott, MBBS PhDFRACP, Judith Trotman, FRACP

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-138945

Published: 2020

NARROW

Safety, tolerability, and activity of the active C1s antibody riliprubart in cold agglutinin disease: a phase 1b study

Using a Quality Improvement Activity to Enhance the Knowledge, Competence and Confidence of Clinicians Managing Patients with Cold Agglutinin Disease

Ethnic Diversity in Presentation of Waldenström Macroglobulinaemia and IgM Mgcs in the United Kingdom- a Real-World Data Analysis

Modified Staging System for Waldenström Macroglobulinemia (MSS-WM): A Multi-Institutional Externally Validated Prognostic Model for Active/Symptomatic Waldenström Macroglobulinemia

Classical Complement Inhibition By SAR445088 (BIVV020) in Adults with Cold Agglutinin Disease: Safety, Tolerability and Activity Results from the Open-Label, Non-Randomized, Single-Dose Phase 1b Study

Pembrowm: Results of a Multi-Centre Phase II Trial Investigating the Safety and Efficacy of Rituximab and Pembrolizumab in Relapsed/Refractory Waldenström's Macroglobulinaemia

Type 1 Cryoglobulinaemia Associated with Waldenström Macroglobulinemia, IgM MGUS or Non-Hodgkin Lymphoma

Adjuvant Systemic Therapy in High Risk Solitary Bone Plasmacytoma: Results of the UK Randomised Phase III IDRIS Study (CR UK/14/032)

Addressing Clinical Management Challenges in the Treatment of Rare, Non-Malignant Hematologic Disorders through Educational Interventions

Sustained Complement C1s Inhibition with Sutimlimab in Patients with Cold Agglutinin Disease Results in Continued Efficacy during Part B of the Randomized Placebo-Controlled Phase 3 Cadenza Study (NCT03347422)

Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial

Effect of ibrutinib treatment on hemolytic anemia and acrocyanosis in cold agglutinin disease/cold agglutinin syndrome

High Frequency of CNS Involvement in Transformed Waldenström Macroglobulinemia

Inhibition of Complement C1s By Sutimlimab in Patients with Cold Agglutinin Disease (CAD): Efficacy and Safety Results from the Randomized, Placebo-Controlled Phase 3 CADENZA Study

Ethnic Disparities in Waldenström's Macroglobulinaemia in the United Kingdom - Analysis from the Wmuk Rory Morrison Registry

Real World Experience on the Use of Ibrutinib Monotherapy in Waldenström Macroglobulinemia

IgM Paraprotein-Associated Type 1 Cryoglobulinaemia: Clinical Characteristics and Outcomes

Autologous Haematopoietic Stem Cell Transplantation in Waldenström Macroglobulinemia: A Single-Centre 18-Year Experience

Global Waldenström's Macroglobulinemia Patient-Derived Data Registry, Whimsical, Highlights Real-World Treatment Outcomes and COVID-19 Data

Whimsical (Waldenstrom's Macroglobulinemia Study Involving CArt-wheeL): A Global Patient-Derived Data Registry Capturing Treatment, Quality of Life and COVID-19 Data

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only